We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Goldseek Resources Inc | CSE:GSK | CSE | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 0.065 | 0.18 | 0 | 00:00:00 |
From Jan 2020 to Jan 2025
LONDON, October 31, 2012 /PRNewswire/ --
GlaxoSmithKline released third quarter results today with Finance Director Simon Dingemans saying the pharma group was on course to deliver growth in Q4 and sales "broadly in line" with the previous year.
In a video interview Mr Dingemans said while factors such as costs from disposals and weak European sales had added to a difficult quarter where total sales were down 5%, performances from promoted and new products plus R&D developments meant shareholders saw dividends up 6% year-on-year.
"I think we're pleased with the progress that the growth drivers and the core strategic businesses are making and I think overall that leaves us feeling that we have good momentum going into the fourth quarter."
The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.
MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.
Copyright 2012 PR Newswire
1 Year Goldseek Resources Chart |
1 Month Goldseek Resources Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
